4. Macrolide Drug

Antimicrobial Drug Use and Macrolide-Resistant Streptococcus pyogenes, Belgium

In Belgium, decreasing macrolide, lincosamide, streptogramins B, and tetracycline use during 1997-2007 correlated significantly with decreasing macrolide-resistant Streptococcus pyogenes during 1999-2009. Maintaining drug use below a critical threshold corresponded with low-level macrolide-resistant S. pyogenes and an increased number of erm(A)-harboring emm77 S. pyogenes with low fitness costs.

Drug Resistance Mechanisms of Mycoplasma pneumoniae to Macrolide Antibiotics

Throat swabs from children with suspected Mycoplasma pneumoniae (M. pneumoniae) infection were cultured for the presence of M. pneumoniae and its species specificity using the 16S rRNA gene. Seventy-six M. pneumoniae strains isolated from 580 swabs showed that 70 were erythromycin resistant with minimum inhibitory concentrations (MIC) around 32-512 mg/L. Fifty M. pneumoniae strains (46 resistan...

Macrolide resistance in Staphylococcus aureus: inducers of macrolide resistance.

Several macrolide-, lincosamide-, and streptogramin B-type (MLS) antibiotics were tested as inducers of erythromycin A (EM)-resistant [(14)C]leucine incorporation. Only 14-membered-ring macrolides having a glycosidically linked 6-deoxy sugar at the C-3 position of the lactone ring and the structurally dissimilar lincosamide, celesticetin, showed inducer activity. Modifications of EM at the C-4'...

Nomenclature for macrolide and macrolide-lincosamide-streptogramin B resistance determinants.

The fall of the Macrolide: Macrolide-resistant Mycoplasma pneumoniae

Mycoplasma pneumoniae (M. pneumoniae) is a major cause of community-acquired pneumonia (CAP) in children, accounting for 10-30% of the etiological agents wor ldwide. Yet , the epidemio logy of M. pneumonia-associated CAP in Hong Kong remains unknown for several reasons. First, there is no systemic surveillance of agents causing CAP in place in Hong Kong. Secondly, serology was the mainstay of d...